These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20634675)

  • 1. A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
    Heras P; Hatzopoulos A; Heras V; Kritikos N; Karagiannis S; Kritikos K
    Am J Ther; 2011 Sep; 18(5):340-2. PubMed ID: 20634675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibandronate: efficacy in the treatment of metastatic bone disease.
    Diel IJ
    Future Oncol; 2005 Oct; 1(5):593-607. PubMed ID: 16556036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bone targeting agents: bisphosphonates].
    Debiais F
    Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of ibandronate in the daily oncological practice].
    Nagykálnai T
    Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for malignancy-related bone disease: current status, future developments.
    Body JJ
    Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
    Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in treatment of metastatic tumors in the bone by bisphosphonate].
    Dong M; Chen XP; Feng FY
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):801-3. PubMed ID: 18396633
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid.
    Yeh DC; Chen DR; Chao TY; Chen SC; Wang HC; Rau KM; Feng YH; Chang YC; Lee KD; Ou-Yang F; Kuo WH; Chang KJ; Lin YC; Tseng LM; Hou MF
    In Vivo; 2014; 28(5):1001-4. PubMed ID: 25189922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
    Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
    Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing metastatic bone pain: the role of bisphosphonates.
    Gralow J; Tripathy D
    J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate.
    Sittig HB
    Onkologie; 2012; 35(6):380-7. PubMed ID: 22722461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
    Mystakidou K; Katsouda E; Stathopoulou E; Vlahos L
    Cancer Treat Rev; 2005 Jun; 31(4):303-11. PubMed ID: 16039956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
    Clemons M; Dranitsaris G; Ooi W; Cole DE
    Breast Cancer Res Treat; 2008 Mar; 108(1):79-85. PubMed ID: 17473981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
    Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
    Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibandronate in metastatic bone pain.
    Heidenreich A; Ohlmann C; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study.
    Mancini I; Dumon JC; Body JJ
    J Clin Oncol; 2004 Sep; 22(17):3587-92. PubMed ID: 15337809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
    Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
    J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.